Marizyme, Inc. (MRZM)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Jul 25, 2025
Marizyme Revenue
Marizyme had revenue of $183.42K in the twelve months ending September 30, 2024, down -68.96% year-over-year. In the year 2023, Marizyme had annual revenue of $645.81K with 176.60% growth.
Revenue (ttm)
183.42K
Revenue Growth
-68.96%
P/S Ratio
0.00
Revenue / Employee
14.11K
Employees
13
Market Cap
132.00
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 645.81K | 412.33K | 176.60% |
Dec 31, 2022 | 233.49K | 23.21K | 11.04% |
Dec 31, 2021 | 210.28K | 13.14K | 6.67% |
Dec 31, 2020 | 197.14K | - | - |
Dec 31, 2019 | - | - | - |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
AMJ Global Technology | 39.00 |
Marizyme News
- 1 year ago - Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ - GlobeNewsWire
- 2 years ago - Marizyme CEO Delivers Business Update - GlobeNewsWire
- 2 years ago - Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™ - GlobeNewsWire
- 2 years ago - Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products - GlobeNewsWire
- 4 years ago - Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office - GlobeNewsWire
- 4 years ago - Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing - GlobeNewsWire
- 4 years ago - Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress - GlobeNewsWire
- 4 years ago - Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories - GlobeNewsWire